expr:href='data:blog.homepageUrl + "favicon.ico"' rel='icon' type='image/x-icon'/> COVAXIN IS SAFE! PASSES PHASE 1 TRIALS WITH SUCCESSFUL PRELIMINARY RESULTS!
-->

COVAXIN IS SAFE! PASSES PHASE 1 TRIALS WITH SUCCESSFUL PRELIMINARY RESULTS!

 COVAXIN IS SAFE! PASSES PHASE 1 TRIALS WITH SUCCESSFUL PRELIMINARY RESULTS!

COVAXIN phase 1 trials
Image Credits: Times Now

After battling the COVID-19 for almost eight months, there finally may be a cure in sight. Russia announced that it had produced the world's first vaccine against the COVID-19. Though there are several doubts raised over the vaccine, it is is enough to give people hope in these tough times. All the countries are currently in a race to bring out the first vaccine against the COVID-19. Though Russia and China may be in the lead, India seems to be catching up. Bharat Biotech's Covaxin entered Phase 1 of its human clinical trials in July 2020. And as per the ICMR, COVAXIN, the vaccine against COVID-19 developed by Bharat Biotech is safe and has passed phase 1 trials. According to the phase 1 preliminary results, COVAXIN is found to be safe.

Bharat Biotech is developing COVAXIN in collaboration with the Indian Council Of Medical Research (ICMR) and the National Institute Of Virology (NIV). Three hundred seventy-five candidates across 12 cities in India have volunteered for the trials, and each individual is injected with a dose of COVAXIN. And after the preliminary phase 1 results, COVAXIN, developed by Bharat Biotech, is found to be safe. The Phase 1 trials have concluded in many cities, and Bharat Biotech is aiming to complete the Phase 1 clinical human trials by August end. Phase 2 human clinical trials of COVAXIN are scheduled to start in September 2020. After Phase 1 human clinical trials of COVAXIN yielded positive results, Bharat Biotech, along with the ICMR and NIV, are much more confident about launching the COVID-19 vaccine, COVAXIN, by the first half of 2021. 

COVAXIN IS SAFE! PASSES PHASE 1 TRIALS WITH SUCCESSFUL PRELIMINARY RESULTS!


According to AIIMS, Delhi, Bharat Biotech is currently in the process of injecting a second dose of COVAXIN to healthy volunteers. No volunteers have displayed any unusual symptoms or side-effects after being injected with two doses of COVAXIN. AIIMS, Delhi has reported that preliminary results of Phase 1 human clinical trials have found that COVAXIN is safe. They expect to have more data on the vaccine once the Phase 1 human clinical trials end by August end. As per the preliminary results of Phase 1 trials, COVAXIN is found to be safe and has had no adverse effects on those who have volunteered for the human clinical trials of COVAXIN.

As per reports, if COVAXIN yields good results throughout, the vaccine against COVID-19 is likely to be unveiled by the first half of 2021. Meanwhile, Phase 2 human clinical trials are due to begin in September 2020  
NEXT ARTICLE Next Post
PREVIOUS ARTICLE Previous Post
NEXT ARTICLE Next Post
PREVIOUS ARTICLE Previous Post
 

Delivered by FeedBurner